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24-norursodeoxycholic acid (norUDCA), a side chain–modifiedursodeoxycholic acid derivative,
has dramatic therapeutic effects in experimental cholestasis andmay be a promising agent for the
treatment of cholestatic liver diseases. We aimed to better understand the physiologic and ther-
apeutic properties of norUDCA and to test if they are related to its side chain length and/or
relative resistance to amidation. For this purpose,Mdr2/mice, a model for sclerosing cholan-
gitis, received either a standard diet or a norUDCA-, tauronorursodeoxycholic acid (tauro-
norUDCA)-, or dinorursodeoxycholic acid (dinorUDCA)-enriched diet. Bile composition,
serum biochemistry, liver histology, fibrosis, and expression of key detoxification and transport
systemswere investigated.Direct choleretic effects were addressed in isolated bile duct units. The
role of Cftr for norUDCA-induced choleresis was explored in Cftr/ mice. norUDCA had
pharmacologic features that were not shared by its derivatives, including the increase in hepatic
and serumbile acid levels and a strong stimulation of biliaryHCO3-output. norUDCAdirectly
stimulated fluid secretion in isolated bile duct units in a HCO3-dependent fashion to a higher
extent than the other bile acids. Notably, the norUDCA significantly stimulatedHCO3-output
also in Cftr/ mice. In Mdr2/ mice, cholangitis and fibrosis strongly improved with
norUDCA, remained unchanged with tauro-norUDCA, and worsened with dinorUDCA. Ex-
pression ofMrp4, Cyp2b10, and Sult2a1 was increased by norUDCA and dinorUDCA, but was
unaffected by tauro-norUDCA. Conclusion: The relative resistance of norUDCA to amidation
may explain its unique physiologic and pharmacologic properties. These include the ability to
undergo cholehepatic shunting and to directly stimulate cholangiocyte secretion, both resulting
in a HCO3-rich hypercholeresis that protects the liver from cholestatic injury. (HEPATOLOGY
2009;49:1972-1981.)
See Editorial on Page 1795
Due to the limited efficacy of current medicaltreatment of chronic diseases of the biliary tree,such as sclerosing cholangitis,1 there is an urgent
need to develop novel treatment strategies and to test
them in animal models for human cholangiopathies.2
Mice lacking the canalicular phosphatidylcholine flop-
paseMdr2 (Abcb4) (Mdr2/mice) develop chronic cho-
lestatic liver disease including sclerosing cholangitis and
biliary fibrosis.3,4 These unique characteristics of
Mdr2/mice are of particular interest because increasing
evidence suggests a key role of MDR3 (ABCB4, the hu-
man orthologue of rodent Mdr2) defects in human cho-
lestatic liver diseases ranging from neonatal cholestasis to
biliary cirrhosis in adults.5 More recently,MDR3 variants
have been observed in patients with primary sclerosing
cholangitis6 and idiopathic biliary fibrosis,7 highlighting
the importance of MDR3 as a modifier gene in disease
course and severity of cholangiopathies.
Abbreviations: dinorUDCA, dinorursodeoxycholic acid; IBDU, isolated bile duct unit; K19, keratin 19; norUDCA, 24-norursodeoxycholic acid; -SMA, -smooth
muscle actin; tauro-norUDCA, tauronorursodeoxycholic acid; UDCA ursodeoxycholic acid.
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We have recently demonstrated that cholangitis and
biliary fibrosis in Mdr2/ mice are reversed by 24-
norursodeoxycholic acid (norUDCA), a C23 homo-
logue of ursodeoxycholic acid (UDCA) with one less
methyl group in its side chain,8 suggesting that side
chain–modified bile acids may represent a novel and
promising treatment strategy for cholestatic liver dis-
eases. The potential therapeutic mechanisms, hypoth-
esized so far to explain the pharmacodynamic effects of
norUDCA in Mdr2/ mice, include increased hydro-
philicity (and decreased cytotoxicity) of the circulating
bile acid pool, induction of detoxification pathways and
elimination routes for bile acids, as well as potential direct
anti-inflammatory and anti-fibrotic effects.8 The therapeutic
effects of norUDCAmay be related to its side chain structure
that strongly influences norUDCAmetabolism.8,9 Themet-
abolic fate of norUDCA differs substantially from that of
other natural bile acids, including UDCA, because of its
minimalN-acyl amidation (conjugation)with taurine or gly-
cine8,9 together with its considerable hydroxylation and glu-
curonidation. In contrast to conjugated bile acids,
unconjugated norUDCA is a weak organic acid with only
two hydroxyl groups that can be reabsorbed from bile by
cholangiocytes and subsequently be resecreted by hepato-
cytes therebyundergoing a cholehepatic shunt, a process that
is associatedwith aHCO3-rich hypercholeresis.10 Flushing
of bile ducts by HCO3-rich bile may dilute and inactivate
toxic biliary contents, thereby protecting bile ducts from fur-
ther injury inMdr2/mice.8 HCO3-rich hypercholeresis
has also been described forUDCA (the parent compound of
norUDCA), although this process only occurs in vitro once
taurine stores have become depleted and the concentration
of unconjugatedUDCAprevails over that of its taurine con-
jugate.11 Recent studies have shown that UDCA is also able
to directly stimulate fluid secretion by cholangiocytes
through Cftr-mediated ATP secretion and apical purinergic
signaling,12 but the potential effects of norUDCA remain to
be elucidated.
To test whether the physiologic and therapeutic prop-
erties of norUDCA are related to its relative resistance to
N-acyl amidation or its side chain length, we compared
norUDCA with tauro-norUDCA (a synthetic taurine
conjugate of norUDCA) and dinorUDCA (a C22 homo-
logue of UDCA and norUDCA with only three carbon
atoms in its side chain) in the Mdr2/ mouse model of
sclerosing cholangitis and biliary fibrosis. Moreover, this
study was designed to test the hypothesis that the phar-
macologic effects of norUDCAdepend on its ability to recir-
culate between bile ducts and hepatocytes as a consequence
of cholehepatic shunting and/or its direct stimulatory effects
on cholangiocyte secretion. This information should be crit-
ical for the design of novel drugs for the treatment of chole-
static liver diseases.
Materials and Methods
Animal Experiments. Mdr2/ mice (FVB/N back-
ground) were obtained from Jackson Laboratory (Bar
Harbor, ME). Eight-week-old male Mdr2/ mice re-
ceived either standard chow (Ssniff, Soest, Germany)
or a diet containing norUDCA, tauro-norUDCA, or
dinorUDCA (0.5% wt/wt, the dosage that corresponds
approximately to 15 mg/mouse/day) over 4 weeks.
Congenic B6.129P2-Cftrtm1Unc mice, which possess
the S489X mutation that blocks transcription of
Cftr,13 were fed with Peptamen (Nestle Clinical Nutri-
tion, Deerfield, IL) or with Peptamen containing
norUDCA (in a dosage equivalent to that used in
Mdr2/ mice) for 1 week. All animals were housed
under a 12:12-hour light/dark cycle and permitted ad
libitum consumption of water and diet. The experi-
mental protocols were approved by the local Animal
Care and Use Committees according to criteria out-
lined in the Guide for the Care and Use of Laboratory
Animals prepared by the U.S. National Academy of
Sciences (National Institutes of Health publication 86-
23, revised 1985).
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Synthesis of norUDCA (3,7-Dihydroxy-5-
cholan-23-oic Acid), tauro-norUDCA [3,7-Dihy-
droxy-5-cholan-23-oic Acid N-(2-Sulfoethyl)amide,
norUDC-tau], and dinorUDCA (3,7-Dihydroxy-5-
cholan-22-oic Acid, bisnorUDCA). The compounds
studied (Supporting Fig. 1) were synthesized from
UDCA as described.1416 Unconjugated bile acids were
pure by thin layer chromatography; tauro-norUDCA was
pure by high-pressure liquid chromatography.
Analysis of Bile Flow and Composition. Bile flow
and composition were determined as described.8 Before
harvesting, mice were anesthetized with tribromoethanol
(Avertin) 250 mg/kg body weight intraperitoneally. The
common bile duct was ligated, and the gallbladder was
cannulated for collection of bile. After a 10-minute equil-
ibration period, bile was collected for 1 hour in test tubes
under mineral oil for determination of HCO3, total car-
bon dioxide and pH using an automatic blood gas ana-
lyzer (AVL 995 hp, AVL, Graz, Austria; COBAS Mira
plus, Roche). For bile flowmeasurements and further bile
analysis, bile was collected for the following 30minutes in
preweighed test tubes. Bile flow was determined gravi-
metrically and normalized to liver weight as described.17
Biliary glutathione concentration was determined after
protein precipitation using 5% metaphosphoric acid
(Glutathione Assay Kit; Calbiochem, La Jolla, CA) ac-
cording to the manufacturer’s instructions. Biliary bile
acid concentration (of 3-hydroxy bile acids) was mea-
sured enzymatically using a colorimetric bile acid kit
(Ecoline S, Holzheim, Germany).
Intrahepatic Mouse Bile Duct Units and Assess-
ment of Ductular Secretion via Video-Optical
Planimetry. Isolated bile duct units (IBDUs)—sealed
fragments of isolated bile ductules with retained polarity
that can secrete into a closed lumen—were prepared, pu-
rified, and cultured as described.1820 Secretion in IBDUs
is determined bymeasuring expansion of their lumen over
time using video-optical planimetry as an indicator of the
ductular secretion rate, as described.1820 After a
5-minute baseline period, IBDUs were exposed to bile
acids (at 250 M concentration) for up to 30 minutes,
and the luminal area was measured every 5 minutes via
video-optical planimetry. Serial images of the IBDUs
were acquired as described.12 To determine whether se-
cretion depends on HCO3, IBDUs were perfused with
either HCO3-free 4-(2-hydroxyethyl)-1-piperazine eth-
anesulfonic acid (HEPES) buffer or HCO3-containing
Krebs-Ringer buffer.
Bile Acid Analysis. Bile acids were extracted from
liver homogenate, serum, and bile and analyzed using
electrospray ionization mass spectrometry and gas chro-
matography mass spectrometry as described.8,21
Routine Serum Biochemistry. Alanine aminotrans-
ferase and alkaline phosphatase were analyzed with a Hi-
tachi 917 analyzer (Boehringer Mannheim, Mannheim,
Germany).
Liver Histology. For conventional light microscopy,
formalin-fixed livers were embedded in paraffin, and
4-m thick sections were stained with hematoxylin-eosin
and Sirius red staining. The sections were coded and ex-
amined by a pathologist (C. L.) who was unaware of the
animals’ genotype and treatment.
Immunohistochemistry for Keratin 19. As de-
scribed, keratin 19 (K19) immunohistochemistry was
performed on cryosections with monoclonal rat anti–
Troma-III antibody (dilution 1:100, Developmental
Studies Hybridoma Bank) developed under the auspices
of the National Institute of Child Health and Human
Development (NICHID) and maintained at the Univer-
sity of Iowa (Iowa City, IA).22
Western Blotting. -Smooth muscle actin (-SMA)
and K19 protein levels were determined in liver homog-
enates (30 g protein) via western blotting as de-
scribed8,23 using monoclonal mouse antibody against
-SMA (dilution, 1:1,500; Sigma-Aldrich, Vienna, Aus-
tria) and monoclonal rat K19 (dilution, 1:1,500; Devel-
opmental Studies Hybridoma Bank). Blots were reprobed
with an anti–-actin antibody (dilution, 1:5,000; Sigma-
Aldrich, Vienna, Austria) to confirm the specificity of the
observed changes in transporter protein levels.
Determination of Hepatic Hydroxyproline Con-
tent. To quantify liver fibrosis, hepatic hydroxyproline
was measured as described.24
Messenger RNA Analysis. Total hepatic RNA was
isolated and reverse-transcribed into complementary
DNA as described.21 In brief, total RNA was isolated
using TRIzol Reagent (Invitrogen, Austria) and re-
verse-transcribed into complementary DNA by using
the GeneAmp Gold RNA PCR Core Kit (Applied Bio-
systems, Vienna, Austria) according to the manufactur-
er’s instructions. Real-time PCR was performed on a
GeneAmp 7900 Sequence Detection System with Ge-
neAmp 7900 SDS software (Applied Biosystems, CA).
Polymerase chain reaction was performed in a 20-L
reaction mixture containing TaqMan or SYBR Univer-
sal PCR Master Mix (Applied Biosystems, CA). Poly-
merase chain reaction products were checked via gel
electrophoresis for correct size and quality. All data
were normalized to 18s ribosomal RNA. The TaqMan
oligonucleotides were as follows: Mrp4 forward primer
5-TTAGATGGGCCTCTGGTTC-3, reverse
primer 5-GCCCACAATTCCAACCTTT-3, probe
5-ACTGCGCTCATCAAGTCCAGGG-3 (Gen-
Bank accession number W54702); Cyp2b10 forward
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primer 5-CAATGGGGAACGTTGGAAGA-3, re-
verse primer 5-TGATGCACTGGAAGAGGAAC-3,
probe 5- TTCGTAGATTCTCTCTGGCCACCAT-
GAGA-3 (GenBank accession number NM_009998);
Sult2a1 forward primer 5-GGAAGGACCACGACT-
CATAAC-3, reverse primer 5-GATTCTTCA-
CAAGGTTTGTGTTACC-3, probe 5-CCC-
ATCCATCTCTTCTCCAAGTCTTTCTTCAG-3
(GenBank accession number L02335). 18sRNA was
determined using SYBR Green Mastermix and forward
primer 5-GTAACCCGTTGAACCCCATT-3, re-
verse primer 5-CCATCCAATCGGTAGTAGCG-3
(GenBank accession number X00686).
Statistical Analysis. Data are reported as the arith-
metic mean  standard deviation of reported animals in
each group. Statistical analysis was performed using SPSS
software. The data were analyzed with a nonparametric
Mann-Whitney U test. A P value 0.05 was considered
significant.
Results
norUDCA and Its Side Chain Derivatives Have
Differing Effects on Bile Flow and Composition. To
test whether side chain modification of norUDCA influ-
enced bile flow and composition in a cholestatic mouse
model, we fed Mdr2/ mice, a model for spontaneous
sclerosing cholangitis and biliary fibrosis,4 with nor-bile
acids. In contrast to the significant increase of bile flow
and biliary output of bile acids, HCO3 and glutathione
by norUDCA treatment in Mdr2/ mice8 (Table 1),
tauro-norUDCA had no effect on glutathione output,
and the effects on HCO3 output were much less pro-
nounced (Table 1). dinorUDCA altered neither bile flow
nor bile acid, HCO3, or glutathione output (Table 1).
Similar to Mdr2/ mice, norUDCA also stimulated bile
flow and bicarbonate output in corresponding wild-type
animals as reported.8 Of note, stimulation of biliary
HCO3 output in wild-type animals was significantly
higher under norUDCA (241.2  45.3 nmol/g liver
weight1/minute1) compared with tauro-norUDCA
(123.6 47.0 nmol/g liver weight1/minute1) and un-
treated controls (44.3  6.5 nmol/g liver weight1/min
1). These differences between norUDCA and tauro-
norUDCA in their ability to induce a HCO3-rich bile
flow both in normal and cholestatic conditions could be
secondary to the potential of norUDCA to undergo chole-
hepatic shunting10 and/or stimulate HCO3-rich
choleresis at the level of the bile ducts 11.
norUDCA Significantly Increases Fluid Secretion
in IBDUs in a Partially HCO3-Dependent Manner.
To directly address the choleretic potential of side chain–
shortened derivatives of UDCA at the cholangiocyte level,
we perfused mouse IBDUs in vitro with norUDCA,
tauro-norUDCA, or dinorUDCA and measured luminal
expansion rates as a marker of cholangiocellular bile secre-
tion.12 IBDUs perfused with UDCA were used as an in-
ternal control as reported.12 In HCO3-containing
media, norUDCA significantly increased cholangiocyte
fluid secretion in IBDUs above the levels obtained by
perfusion with equimolar amounts of tauro-norUDCA
and UDCA, while the stimulation of the secretion by
dinorUDCA was the lowest (Table 2). In HCO3-free
conditions, bile acid–induced cholangiocyte secretion
was drastically reduced, but not abolished. The stimula-
tion of cholangiocyte secretion in the absence of HCO3
was similar for both norUDCA and tauro-norUDCA in
contrast to previously mentioned differences in HCO3-
containing medium (Table 2). These results strongly ar-
gue for the concept that norUDCA directly stimulates
fluid and HCO3 secretion in cholangiocytes in addition
to stimulating canalicular bile flow.
norUDCA-Induced Stimulation of Biliary HCO3
Output In Vivo Is Partly Cftr-Independent. To fur-
ther understand norUDCA’smechanisms of action and to
test whether norUDCA-induced HCO3-rich hyper-
choleresis is Cftr-dependent, we fed wild-type and Cftr
knockout (Cftr/) mice with norUDCA for 1 week. In
wild-type littermates, norUDCA significantly increased
HCO3 output (5.2-fold) and bile flow (3.2-fold) (Table
3). In Cftr/ mice norUDCA also stimulated HCO3
Table 1. Bile Flow and Composition in Mdr2/ Mice under nor-Bile Acid Treatment
Variable
Control
(n  8)
norUDCA
(n  8)
T-norUDCA
(n  8)
dinorUDCA
(n  4)
Bile flow (L/gLW1/min1) 2.1 0.2 3.4 0.4* 3.1 0.5* 1.9 0.2†
Bile acid output (nmol/gLW1/min1) 10.1 2.5 21.7 7.4* 18.5 4.9* 10.8 2.0†
Bicarbonate output (nmol/gLW1/min1) 56.4 4.0 104.4 22.3* 76.8 12.5*,† 50.8 6.7†
Glutathione output (nmol/gLW1/min1) 3.9 1.2 6.5 1.0* 4.1 0.7*,† 4.7 1.1†
Values are expressed as the mean  standard deviation. Control, standard chow-fed animals; norUDCA, norUDCA–fed animals; T-norUDCA, tauro-norUDCA–fed
animals; dinorUDCA, dinorUDCA–fed animals.
*P  0.05 versus control.
†P  0.05 versus norUDCA.
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output, while the increase in bile flow failed to reach
statistical significance (P 0.053). Of note, the degree of
stimulation of HCO3 output (5.8-fold) and bile flow
(3.3-fold) by norUDCA in Cftr/ mice was similar to
that achieved in wild-type mice. In line with these in vivo
findings, norUDCA also stimulated fluid secretion in IB-
DUs from Cftr/mice, although to a lower extent com-
pared with IBDUs from wild-type animals (data not
shown). Collectively, these finding suggest that
norUDCA is able to generate a biliary HCO3 secretion
also in conditions characterized by defective Cftr. Of
interest, the stimulation of glutathione output by
norUDCA in wild-type animals was abrogated in Cftr/
mice (Table 3). Furthermore, the amount of bile acid
output was lower in Cftr/ mice, a finding consistent
with the production of less alkaline bile in Cftr-defective
animals.
norUDCA and tauro-norUDCA Feeding Increases
Biliary Bile Acid Hydrophilicity. To investigate
whether the replacement of hydrophobic (cytotoxic) bile
acids in phospholipid-depleted bile of Mdr2/ mice by
more hydrophilic ones may contribute to the therapeutic
mechanisms of norUDCA, we next determined the bile
acid composition in Mdr2/ mice treated with
norUDCA and its analogues (Table 4). Bile acid feeding
did not increase biliary bile acid concentrations compared
with controls. Bile acids were efficiently conjugated with
taurine in untreated Mdr2/ mice, as no unconjugated
bile acids were present. In contrast, unconjugated bile
acids were present in all three bile acid–fed groups. In
mice receiving norUDCA, about the half of bile acids
were present in unconjugated form. In animals receiving
tauro-norUDCA, 14%were not taurine–conjugated, and
in animals receiving dinorUDCA only 7% of biliary bile
acids were unconjugated. The presence of taurine-conju-
gated bile acids in mice receiving norUDCA can be ex-
plained by the ability of the ileal transport system to
absorb and thereby conserve the small fraction of
norUDCA that undergoes taurine conjugation. Con-
versely, the presence of unconjugated bile acids in mice
receiving tauro-norUDCA results from tauro-norUDCA
undergoing deconjugation by intestinal bacteria with ab-
sorption of norUDCA. The failure of dinorUDCA to alter
biliary bile acid composition is remarkable. It suggests
that dinorUDCA is poorly absorbed by the gastrointesti-
nal tract. The only major biotransformation of any of the
bile acid was 6-hydroxylation to form -muricholic or
nor--muricholic acid (nor--MCA). Electrospray ion-
ization mass spectrometry could also confirm the excre-
tion of minor amounts of nonamidated norUDCA- and
nor--MCA-glucuronides and sulfates.
norUDCA Is Highly Enriched in Liver and Serum
of Mdr2/ Mice. As shown in Table 4, concentrations
of bile acids in serum and liver were 4 to 5 times higher in
the norUDCA group compared with controls, whereas
Table 2. Effect of nor-Bile Acids on Fluid Secretion in IBDUs
using HCO3- Containing and HCO3-Free Buffer
Variable
% Increase in
Luminal Area after
30 Minutes n P value
HCO3 buffer
Control 12 5 9
UDCA 250 M 42 13 9 0.001*
norUDCA 250 M 65 21 33 0.001*
0.01‡
T-norUDCA 250 M 49 18 18 0.001*
0.05†
NS‡
dinorUDCA 250 M 29 12 18 0.01*
0.001†
0.05‡
HCO3-free HEPES buffer
Control 15 5 8
norUDCA 250 M 31 11 10 0.01*
T-norUDCA 250 M 33 7 8 0.01*
NS†
dinorUDCA 250 M 21 12 8 NS*
NS†
Values are expressed as the mean  standard deviation.
Abbreviations: HEPES, 4-(2-hydroxyethyl)-1-piperazine ethanesulfonic acid; NS,
not significant.
*P  0.05 versus control.
†P  0.05 versus norUDCA 250 M.
‡P  0.05 versus UDCA 250 M.
Table 3. Bile Flow and Composition in Wild-Type and Cftr/ Mice with or without norUDCA Treatment
Variable
Wild-Type Cftr/
Control
(n  4)
norUDCA
(n  4)
Control
(n  3)
norUDCA
(n  5)
Bile flow (L/gLW1/min1) 0.8 0.2 2.6 0.6* 0.6 0.4 2.0 0.8
Bile acid output (nmol/gLW1/min1) 17.9 4.7 34.4 9.2 10.9 7.9 18.9 6.0†
Bicarbonate output (nmol/gLW1/min1) 24.3 6.0 127.2 40.5* 14.3 6.5 83.2 39.3*
Glutathione output (nmol/gLW1/min1) 3.1 0.7 5.3 1.2* 2.5 2.1 2.7 1.2†
Mice were fed a control diet or a diet containing norUDCA for 1 week. Values are expressed as the mean  standard deviation.
*P  0.05 wild-type norUDCA versus wild-type control, Cftr/ norUDCA versus Cftr/ control.
†P  0.05 Cftr/ control versus wild-type control, Cftr/ norUDCA versus wild-type norUDCA.
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bile acid levels did not change after tauro-norUDCA and
dinorUDCA feeding (Table 4). Similar to bile, 43% to
50% of liver and serum norUDCA and its metabolites
were nonamidated. The composition of serum and liver
bile acids in the other groups did not differ significantly
from that found in the bile (data not shown).
norUDCA Is Superior to tauro-norUDCA and di-
norUDCA in Improving Cholestatic Liver Injury in
Mdr2/Mice. We next determined the impact of these
differential pharmacologic mechanisms on the therapeu-
tic efficacy of the nor-bile acids on cholestatic liver injury
in Mdr2/ mice. norUDCA feeding significantly im-
proved serum alanine aminotransferase and alkaline phos-
phatase levels (Table 5) and liver histology (Fig. 1 and
Supporting Fig. 2) as described.8 In contrast to
norUDCA, the reduction of alanine aminotransferase and
alkaline phosphatase levels in response to tauro-
norUDCA feeding was less pronounced and dinorUDCA
treatment worsened liver biochemistry (Table 5). Peri-
ductal fibrosis on hematoxlin-eosin and Sirius red stain-
ing was markedly reduced by norUDCA treatment (Fig.
1A and Supporting Fig. 2); in agreement, -SMA protein
levels were reduced as well (Fig. 1B). In contrast, tauro-
norUDCA and dinorUDCAhad only negligible effects on
-SMA expression levels (Fig. 1B). Increased hepatic hy-
droxyproline content (205  61 g/g liver) in Mdr2/
mice, reflecting liver fibrosis, was significantly reduced by
norUDCA treatment (129  25 g/g liver), whereas
tauro-norUDCA and dinorUDCA did not have a signifi-
cant effect on liver hydroxyproline levels (172  47 and
187  96 g/g liver, respectively). norUDCA feeding
reversed the ductular reaction, as evidenced by signifi-
cantly lower hepatic K19 protein levels, serving as a spe-
cific cholangiocyte marker (Fig. 2A). On the other hand,
tauro-norUDCA had no effect on the ductular reaction
(Fig. 2A), and dinorUDCA increased ductular mass, most
Table 4. Bile Acid Concentration in Serum, Liver, and Bile: Biliary Bile Acid Composition In Mdr2/ Mice under nor-Bile
Acid Treatment
Variable
Control
(n  6)
norUDCA
(n  6)
T-norUDCA
(n  6)
dinorUDCA
(n  4)
Serum (mol/L) 57 12 313 80* 95 41† 60 10†
Liver (nmol/g) 69 27 307 81* 106 40† 109 45†
Bile (mmol/L) 4.3 1.4 4.2 2.2 3.8 2.3 2.9 0.5
Biliary bile acids (rel. %)
Taurine-amidated
Cholic 36.9 0.6 8.1 0.9 12.1 2.1 35.4 0.9
Allocholic 0.1 0.1 0.1 2.3 0.9
Chenodeoxycholic 3.9 0.6 0.1 0.1 3.9 0.3
Ursodeoxycholic 0.6 0.3 0.8 0.4 1.1 0.6 0.6 0.3
-Muricholic 40.2 1.7 4.4 0.7 3.8 0.6 34.0 0.9
-Muricholic 3.4 0.6 1.3 1.1 0.3 0.2 8.4 0.9
-Muricholic 6.2 1.6 0.6 0.4 0.6 0.4 5.7 0.3
norUDCA 0.1 23.1 1.2 56.2 5.5 0.1
nor-Muricholic 0.1 11.0 1.1 11.7 1.9 0.1
Glucuronidated, non-amidated
nordiol 0.1 5.6 2.3 2.4 2.1 0.1
nortriol 0.1 3.1 1.5 0.8 0.7 0.1
Non-amidated, non-glucuronidated
norUDCA 0.1 13.2 0.9 0.2 1.4 0.1
nor-Muricholic 0.1 17.1 2.4 0.4 0.4 0.1
norol-one 0.1 9.0 2.3 8.4 2.7 0.1
nordiol-sulfate 0.1 1.5 1.1 0.4 0.4 0.1
dinorUDCA 0.1 0.1 0.1 6.4 0.5
dinorol-one 0.1 0.1 0.1 0.4 0.3
Control, standard chow-fed animals. T-norUDCA, T-norUDCA-fed animals. Values are expressed as the mean  standard deviation. Values do not add up to 100%
because trace bile acids (1%) are not shown.
*P  0.05 versus control.
†P  0.05 versus norUDCA.
Table 5. Effects of nor-Bile Acids on Liver Enzymes in
Mdr2/ Mice
Variable
Control
(n  10)
norUDCA
(n  8)
T-norUDCA
(n  9)
dinorUDCA
(n  7)
ALT (U/L) 395 101 272 35* 331 100 903 177*,†
AP (U/L) 212 33 170 22* 188 34 940 175*,†
Control, standard chow-fed animals; norUDCA, norUDCA–fed animals;
T-norUDCA, tauro-norUDCA–fed animals; dinorUDCA, dinorUDCA–fed animals.
Values are expressed as the mean  standard deviation.
*P  0.05 versus control.
†P  0.05 versus norUDCA.
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Fig. 1. norUDCA is more effective than tauro-norUDCA and dinorUDCA in reducing biliary fibrosis in Mdr2/ mice. (A) Sirius red staining of liver
in standard chow-fed (control), norUDCA-fed, tauro-norUDCA-fed (T-norUDCA), and dinorUDCA-fed Mdr2/ mice. Compared with striking reduction
of fibrosis with periductal collagen fibers (red) in norUDCA-treated Mdr2/ mice, the effects of tauro-norUDCA and dinorUDCA were much weaker
(magnification 20). bd, bile duct; pv, portal vein. (B) Western blot analysis of hepatic -SMA protein levels (marker for activated myofibroblasts)
in liver homogenates of standard chow-fed (control), norUDCA-fed, tauro-norUDCA-fed (T-norUDCA), and dinorUDCA-fed Mdr2/ mice. Densitometry
data are expressed as n-fold change relative to standard chow-fed Mdr2/ mice. Values are expressed as the mean  standard deviation. Note
a significant decrease in -SMA protein levels by norUDCA treatment. *P  0.05 versus control.
Fig. 2. norUDCA, but not tauro-norUDCA and dinorUDCA, reduce ductular proliferation in Mdr2/ mice. (A) Immunohistochemistry of
cholangiocytes using an anti-K19 antibody in standard chow-fed (control), norUDCA-fed, tauro-norUDCA-fed (T-norUDCA), and dinorUDCA-fed
Mdr2/ mice (magnification 20). Ductular proliferation in standard chow-fed Mdr2/ mice was reduced by norUDCA and remained unchanged
after tauro-norUDCA. dinorUDCA even increased ductular proliferation in Mdr2/ mice. (B) Western blot analysis of hepatic K19 protein levels in
liver homogenates of standard chow-fed (control), norUDCA-fed, tauro-norUDCA-fed (T-norUDCA), and dinorUDCA-fed Mdr2/ mice. Densitometry
data are expressed as n-fold change relative to standard chow-fed Mdr2/ mice. Values are expressed as the mean  standard deviation. Note
the significant decrease in K19 protein levels by norUDCA and significant increase by dinorUDCA. *P  0.05 versus control. #P  0.05 versus
norUDCA.
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likely as a result of aggravation of liver injury. Western
blotting for K19 (Fig. 2B) demonstrated a significantly
reduced expression by norUDCA, no effects by tauro-
norUDCA, and an increase in K19 protein mass by di-
norUDCA (Fig. 2B).
Effects of norUDCA and Its Side Chain Derivatives
on Bile Acid Detoxification and Alternative Export.
To study the possible role of induction of bile acid detox-
ifying enzymes and adaptive transporter expression, we
determinedmessenger RNA expression levels of key phase
I (Cyp2b10) and phase II (Sult2a1) detoxifying enzymes
as well as phase III export system Mrp4, because these
gene products have been identified as key targets of
norUDCA.8 Cyp2b10, Sult2a1, and Mrp4 were highly
up-regulated in response to norUDCA treatment (Fig. 3),
whereas induction by tauro-norUDCA was less pro-
nounced. In contrast to its toxic effects on cholestatic liver
injury, dinorUDCA feeding resulted in a robust increase
of Cyp2b10, Sult2a1, and Mrp4 (Fig. 3).
Discussion
norUDCA has been shown to cure liver injury in
Mdr2/ mice.8 Comparing different norUDCA ana-
logues, we now show that the therapeutic properties of
norUDCA in the Mdr2/ mouse model for sclerosing
cholangitis and portal fibrosis are unique and not shared
by its analogues tauro-norUDCA and dinorUDCA.Most
importantly, we demonstrate that the unique pharmaco-
dynamic effects of norUDCA depend on its relative resis-
tance to taurine conjugation, its ability to undergo
cholehepatic shunting with stimulation of canalicular bile
flow, and its direct stimulation of cholangiocyte secretion.
The therapeutic effects of norUDCA are highly spe-
cific. Conjugation with taurine (resulting in tauro-
norUDCA), as well as further side chain shortening (i.e.,
dinorUDCA) resulted in a marked reduction or even
complete abrogation of its therapeutic properties, respec-
tively. Our data indicate that the effectiveness of
norUDCA in comparison with the other UDCA deriva-
tives correlates with its ability to induce a hydrophilic,
HCO3-rich choleresis of both canalicular and ductal or-
igin that may flush the injured bile ducts.8 Previous find-
ings by Yoon et. al. on the choleretic properties of
norUDCA in three rodent species10 indicate that
norUDCA may undergo cholehepatic shunting. This
multistep process includes reabsorption of the unconju-
gated protonated, lipophilic bile acid by cholangiocytes,
and transport into the periductal capillary plexus, which
drains into sinusoids leading to hepatocellular reuptake
and canalicular re-excretion into bile. A key physicochem-
ical property of bile acids that undergo cholehepatic
shunting is that they are weak organic acids that are easily
protonated and are able to cross cell membranes rapidly,
presumably by a passive mechanism. Taurine conjugation
results in a bile acid being present as a charged anion that
can only undergo cholehepatic shunting via apical sodi-
um-dependent bile acid transporter Asbt,25 as taurine
conjugation renders bile acids membrane-impermeable,
thus limiting the HCO3 generation in bile. Cholehe-
patic shunting of bile acids may therefore ensue when
taurine stores are depleted or conjugation-resistant bile
acids are administered.10 In our experimental conditions,
the concept of cholehepatic shunting is further supported
by the abundance of unconjugated norUDCA in the liver.
These data therefore underline the concept that the ther-
apeutic superiority of norUDCAmay indeed be related to
its relative resistance to conjugation, as well as its capacity
to undergo cholehepatic shunting and to stimulate cana-
licular bile flow and HCO3-rich hypercholeresis.
Fig. 3. Effects of nor-bile acids on hepatic messenger RNA expression of phase I and II detoxification enzymes and alternative bile acid transporter.
Relative messenger RNA expression of Cyp2b10, Sult2a1, and Mrp4 of standard chow-fed (control), norUDCA-fed, tauro-norUDCA-fed (T-norUDCA),
and dinorUDCA-fed Mdr2/ mice. Values are expressed as n-fold change compared with the control group (mean  standard deviation of five
animals). norUDCA and dinorUDCA induced both detoxification enzymes Cyp2b10 and Sult2a1 as well as alternative export pump Mrp4. The effects
of T-norUDCA were less pronounced. *P  0.05 versus control. #P  0.05 versus norUDCA.
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As shown previously, UDCA, the parent compound of
norUDCA, directly stimulates fluid secretion in isolated
cholangiocytes through a Cftr-dependent secretion of
ATP that, in turn, interacts with apical purinergic recep-
tors, which then stimulate Ca2-dependent Cl channels
to secrete Cl. The secreted Cl is subsequently ex-
changed with HCO3 by the apical anion exchanger
AE2.12 To study whether norUDCA has direct choleretic
effects on cholangiocytes, we measured the secretory ef-
fects of the three bile acids by quantifying luminal expan-
sion in IBDUs. In line with the choleretic effect observed
in vivo, norUDCA had the strongest effect on ductular
secretion in IBDUs. Secretory effects of nor-bile acids
were for the most part HCO3-dependent. Incubation of
IBDUs with a HCO3-free buffer reduced norUDCA-
stimulated fluid secretion by more than half, by one third
for tauro-norUDCA and minimally for dinorUDCA. In-
vestigating the mechanisms of these additional HCO3-
independent mechanisms was, however, beyond the
scope of the present study.
Further experiments with norUDCA in Cftr/ mice
now indicate that norUDCA-induced HCO3 secretion
is partly Cftr-independent. This stimulation of biliary
HCO3 excretion by norUDCA via an at least partly
Cftr-independent mechanism should encourage the use
of norUDCA as a potential therapeutic strategy in cystic
fibrosis-associated hepatobiliary disease. Reduced bile
acid output in norUDCA-treated Cftr/ mice is likely
due to the lower biliary pH that promotes protonation
and reabsorption of norUDCA. This observation also
provides an explanation as to why hypercholeretic bile
acids directly stimulate HCO3secretion in cholangio-
cytes. It is attractive to speculate that the mechanisms
could have evolved to improve the biliary disposal of po-
tentially toxic weak organic acid compounds that other-
wise would continue to recirculate in the liver. In fact,
HCO3 secretion by bile ducts would be predicted to
reduce their protonation and increase the biliary disposal
of cholephiles.
The unique combination of cholehepatic shunting
(which induces canalicular bile flow) and direct induction
of a HCO3-dependent secretion from cholangiocytes8
may exert a flushing effect on the injured biliary tree,
likely removing and inactivating toxic compounds. In
contrast to the beneficial choleretic effects of norUDCA,
UDCA-induced choleresis has been shown to result in
disruption of cholangioles and aggravation of liver injury
in the Mdr2/ model for sclerosing cholangitis.4 The
underlying mechanism for these puzzling differences re-
mains to be resolved, but could include differences in the
capability of directly stimulating ductular secretion. Nev-
ertheless, future clinical trials should take into account
potential detrimental norUDCA effects in the context of
frank biliary obstruction.
The effects of different nor-bile acids on liver fibrosis
were closely linked to their effects on ductular reaction,
which has been postulated to trigger biliary fibrosis in
mice and humans.22,26,27 Also in our studies the amount
of liver fibrosis in treated animals correlated with the
amount of ductular reaction. norUDCA reduced both
ductular proliferation and biliary fibrosis. Although
norUDCA reversed only the pathologically enhanced
ductular hyperproliferation in Mdr2/ mice and never
induced ductopenia in wild-type animals, we cannot def-
initely rule out the theoretical risk for development of
ductopenia in humans with vanishing bile duct syn-
dromes. Future clinical pilot trials should therefore con-
sider only patients without advanced ductopenia. In
comparison to norUDCA, dinorUDCA-treated Mdr2/
mice showed a brisk induction of the ductular reaction
that likely reflects a regenerative response to increased
liver injury, as suggested by significantly increased serum
aminotransferases. In contrast to the findings inMdr2/
mice, wild-type mice fed with the same dosage of di-
norUDCA with similar hepatic enrichment had induced
bile flow, but did not show any alterations in liver en-
zymes or liver histology excluding a general toxic effect
(data not shown).
Bile acids are able to directly stimulate their metabo-
lism and export by the induction of hepatic phase I and
phase II detoxification systems as well as by induction of
basolateral and apical bile acid transporters.28 These
mechanisms, promoting detoxification of bile acids to
more water-soluble derivatives and facilitating their excre-
tion via the kidney, could counteract the effects of cho-
lestasis and liver injury.28 In line with a previous study,8
norUDCA feeding resulted in a robust induction of phase
I and phase II detoxification enzymes, explaining the in-
creased appearance of polyhydroxylated, sulfated, and
glucuronidated norUDCAmetabolites in bile, serum, and
urine in mice and in humans.8,9 Similar biotransforma-
tion patterns seem to be common to other nor-bile acids as
shown previously for norchenodeoxycholic and dinorch-
enodeoxycholic acid, both being amidation-resistant and
glucuronidated in the hamster and the rat.29 Taurine con-
jugation abrogated the effects of norUDCA on induction
of Cyp2b10, Sult2a1, and the basolateral export pump
Mrp4. Astonishingly, dinorUDCA effects on expression
of detoxifying and export systems were comparable with
those of norUDCA, despite its toxic effect in Mdr2/
mice. Therefore, the observed induction of detoxifying
and alternative export systems is not likely to represent a
central therapeutic mechanism, and could rather support
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a secondary response to injury or to the accumulation of
nor-bile acids.
In conclusion, this comprehensive analysis of the dif-
ferential physiologic and therapeutic mechanisms of
norUDCA and its derivatives tauro-norUDCA and di-
norUDCA clearly demonstrates the therapeutic superior-
ity of norUDCA in an animal model for sclerosing
cholangitis and biliary fibrosis (Supporting Table 1). The
differential effects of the various nor-bile acids depend on
specific properties that affect their ability to undergo
cholehepatic shunting, thereby stimulating canalicular
bile flow as well as by directly stimulating fluid secretion
by cholangiocytes. These datamay have high relevance for
the design of novel pharmacologic treatments for cholan-
giopathies and liver diseases in general.
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